Press Releases

Mar 17, 2021

Feb 02, 2021

Harbour BioMed and ProBioGen agree on a GlymaxX® License to Fast-Track Cell Line Development Projects

Jan 21, 2021

ProBioGen licenses GlymaxX® Technology to AbbVie

Nov 18, 2020

Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline

Oct 27, 2020

ProBioGen’s Productivity increasing Pathway Modulator Technology used by ImmunOs Therapeutics

Oct 22, 2020

Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services

Apr 28, 2020

ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

Mar 24, 2020

Immunogenesis contracts ProBioGen for Development and Large-Scale Manufacturing Services

Feb 25, 2020

ImmunOs Therapeutics selects ProBioGen for Development and Large-Scale Manufacturing Services

Jan 14, 2020

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule

Page 2 of 9

Press Releases

ProBioGen licenses GlymaxX® Technology to Sanofi

Harbour BioMed and ProBioGen agree on a GlymaxX® License to Fast-Track Cell Line Development Projects

ProBioGen licenses GlymaxX® Technology to AbbVie

Asahi Kasei Pharma contracts ProBioGen for the Advancement of their Biologics Pipeline

ProBioGen’s Productivity increasing Pathway Modulator Technology used by ImmunOs Therapeutics

Heidelberg Pharma contracts ProBioGen for Cell Line Development and Manufacturing Services

ProBioGen AG appoints Dr. Lutz Hilbrich as new Chief Executive Officer - Dr. Wieland Wolf retires

Immunogenesis contracts ProBioGen for Development and Large-Scale Manufacturing Services

ImmunOs Therapeutics selects ProBioGen for Development and Large-Scale Manufacturing Services

ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule